Andrew Blumenfeld, MD: Long-Term OnabotulimuntoxinA Use in the COMPEL Study
May 20th 2020The director of the Headache Center of Southern California discussed the findings of the study, as well as what these data might suggest about how onabotulinumtoxinA fits into the shifting landscape of chronic migraine care.
Amy Sullivan, PsyD, ABPP: Interdisciplinary Care in MS
May 20th 2020The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of interdisciplinary care and ways it can be incorporated for patients with multiple sclerosis.
Howard Fillit, MD: Aducanumab Findings Lead the Way in Dementia
May 20th 2020The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation discussed the landmark findings from Biogen on its agent aducanumab and the impact the trial might have on the future.